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Purpose/Objective: Boluses are used in high-energy 
radiotherapy in order to overcome the skin sparing effect. In 
practice though, commonly used flat boluses fail to make a 
perfect contact with the irregular surface of the patient’s 
skin, resulting in air gaps. Hence, we fabricated a customized 
bolus using a 3-dimensional (3D) printer and evaluated its 
feasibility for radiotherapy. 
Materials and Methods: We designed two kinds of bolus for 
production on a 3D printer, one of which was the 3D printed 
flat bolus for the Blue water phantom and the other was a 3D 
printed customized bolus for the RANDO phantom. The 3D 
printed flat bolus was fabricated to verify its physical quality. 
The resulting 3D printed flat bolus was evaluated by assessing 
dosimetric parameters such as D1.5cm, D5cm, and D10cm. 
The 3D printed customized bolus was then fabricated, and its 
quality and clinical feasibility were evaluated by visual 
inspection and by assessing dosimetric parameters such as 
Dmax, Dmin, Dmean, D90%, and V90%. 
Results: The dosimetric parameters of the resulting 3D 
printed flat bolus showed that it was a useful dose escalating 
material, equivalent to a commercially available flat bolus. 
Analysis of the dosimetric parameters of the 3D printed 
customized bolus demonstrated that it is provided good dose 
escalation and good contact with the irregular surface of the 
RANDO phantom. 
Conclusions: A customized bolus produced using a 3D printer 
could potentially replace commercially available flat boluses.  
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Purpose/Objective: Quality control of radiotherapy 
treatment plans includes secondary independent calculation 
of monitor units. However, with the development of new 
technology, this single point calculation is getting less 
relevant and does not always permits an informed decision. 
The aim of this study is to investigate the ability of a 
commercial software (Mobius 3D, FX,version 4.1, Mobius 
Medical Systems, Houston, TX) to propose an integrated 
solution from calculation to delivery while decreasing control 
time on treatment units. 
Materials and Methods: Our department uses several TPS 
with different algorithms (Isogray v4.2, Eclipse v10, 
Tomotherapy v5). Various treatment technics (VMAT, 
dynamic IMRT, classical 3D conformal for Clinac and 
TomoTherapy) are available.  
Mobius V4.1 was used with golden data provided by vendors 
to test our beam modeling. The algorithm used is collapsed 
cone convolution superposition with 144 isotropically-spaced 
cones, a step size always inferior to a voxel and high 
resolution kernels. It provides independent monitor unit 
calculation, 3D isodoses statistics and dosimetric benchmark. 
For Varian treatment, uploading dynalog files in this software 
permits calculation of the difference between the calculated 
and delivered leaf positions and its impact on 3D dose 
calculation. 
Results: We have validated the commercial software by 
increasing difficulties from unmodulated to modulated field, 
on a cubic homogeneous phantom then on a round 
heterogeneous one. Difference between TPS and Mobius were 
inferior to 0.5% for UM calculation for 3D conformal 
treatment and up to 0.6% differences on mean doses. Gamma 
passing rate (3%-3mm) was up to 100%. 
For rapid arc patient, differences for mean doses were 
between 0.9 and 2%; up to 2.3% UM difference. Gamma 
passing rate was 99.7% for (3%-3mm). 
For Tomotherapy treatment, calculated dose distribution 
shows mean gamma passing rate of 99.6%+/-1.15%. 
Conclusions: To have a multi-brand environment complicates 
the legal independent monitor unit calculation; a complete 
solution in one software accessible from every institutional 
PC facilitates the workflow. Tools as risk of collision, 
templates of dosimetric alert thresholds positions the 
software in a global context of quality treatment plans 
preparation, planning, treatment (taking into account the 
actual position of the leafs). As far as we know, this is the 
only software doing a second calculation of dose distribution 
for Tomotherapy. 
Is this change in the quality evaluation of treatment plans 
another step towards safety? Preliminary results show this 
solution permits to analyse every step of the process. 
Next step will be to analyze the possibility to replace the 
treatment plans measurements by automatic analysis to 
optimize treatment machine availability for treatment. 
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Purpose/Objective: To compare and analyze the dosimetry 
characteristics of volumetric modulated arc therapy(VMAT) 
versus constant dose?rate and constant angular spacing 
intensity modulated arc therapy(CDR-CAS-IMAT) in the 
treatment of esophagus cancer. 
Materials and Methods: Twenty four patients with 
esophageal cancer were selected, including 6 cases located in 
the cervical, the upper, the middle and the lower thorax, 
respectively. CDR-CAS-IMAT and VMAT plans were generated 
with the Oncentra planning system on Varian 23IX 
conventional linear accelerator and Elekta Synergy™ new 
accelerator. Prescription dose of 60Gy in 30 fractions, 
planning objectives for PTV were at least 95% reached the 
prescription dose and V110 no more than 10%. The maximum 
dose of spinal?cord below 45Gy and double lung dose 
V20≤28%, V30≤18% were constrained. PTV and tissue dose 
volume parameters statistic by dose value histogram, and 
additional machine MU, treatment time and gamma index 
comparisons were performed. Using SPSS 19.0 software apply 
paired T?test analysis two sets of data.  
Results: CDR-CAS-IMAT group compared with VMAT group 
showing that PTV's CI?D2; CTV's Dmax,HI,CI; cardiac's 
V40,V45,V50; lung's V30, and the treatment time were better 
